In this open-label study , we initially randomly assigned @ previously untreated patients with HCV genotype @ infection and @ patients infected with HCV genotype @ or @ to daclatasvir at a dose of @ mg orally once daily plus sofosbuvir at a dose of @ mg orally once daily , with or without ribavirin , for @ weeks .